Holen Sie sich die Stockscreener-App
14.28
0.07%
0.010
Anika Therapeutics Inc Aktie (ANIK) Neueste Nachrichten
Anika Therapeutics (NASDAQ:ANIK) Share Price Crosses Above 200-Day Moving AverageTime to Sell? - MarketBeat
Anika Therapeutics (ANIK) SVP Ian McLeod granted RSUs and PPSARs - Stock Titan
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
If You Invested $1,000 in Anika Therapeutics Inc (ANIK) - Stock Titan
ANIK Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Regenerative Medicine Market Is Going to Boom | Anika Therapeutics, Inc. and Arthrex - openPR.com
Anika Therapeutics Forms Golden Cross, Signaling Potential Bullish Breakout - Markets Mojo
Anika Therapeutics (ANIK) EVP reports RSU vesting and tax share withholding - Stock Titan
Anika Therapeutics (NASDAQ: ANIK) CEO adds shares via RSU vesting and award - Stock Titan
Anika Therapeutics (ANIK) director vests RSUs, withholds shares for taxes - Stock Titan
Anika Therapeutics (NASDAQ: ANIK) SVP gains shares via RSUs, covers taxes with stock - Stock Titan
Precision Trading with Anika Therapeutics Inc. (ANIK) Risk Zones - Stock Traders Daily
Anika Therapeutics (NASDAQ:ANIK) Shares Pass Above 200-Day Moving Average – What’s Next? - Defense World
Anika Therapeutics (NASDAQ:ANIK) Shares Pass Above 200-Day Moving AverageWhat's Next? - MarketBeat
Anika Therapeutics falls after its completes divestiture of Parcus Medical business - TradingView
Anika Therapeutics (ANIK) EVP’s RSUs Vest with Shares Withheld for Taxes - Stock Titan
Anika Therapeutics (ANIK) director nets RSU shares after tax withholding - Stock Titan
Anika Therapeutics (ANIK) SVP RSUs vest; 639 shares withheld for taxes - Stock Titan
Anika signals 1%–9% revenue growth outlook for 2026 while expanding commercial channel and streamlining operations - MSN
Anika Therapeutics Earnings Call Signals Cautious Rebound - TipRanks
Jobs Data: Will Anika Therapeutics Inc. (AKP) stock gain from lower interest ratesWeekly Loss Report & Capital Efficiency Focused Ideas - Naître et grandir
Anika Therapeutics (NASDAQ:ANIK) Rating Increased to Strong-Buy at Wall Street Zen - MarketBeat
Bank Watch: Is Anika Therapeutics Inc still a buy after recent gains2025 AllTime Highs & Free Growth Oriented Trading Recommendations - baoquankhu1.vn
Published on: 2026-03-07 10:02:22 - baoquankhu1.vn
Trigran Investments Inc. Sells 415,296 Shares of Anika Therapeutics Inc. $ANIK - MarketBeat
Technical Reactions to ANIK Trends in Macro Strategies - Stock Traders Daily
Top 2 Health Care Stocks That May Crash This QuarterArcellx (NASDAQ:ACLX), Anika Therapeutics (NASDAQ:ANIK) - Benzinga
Anika Therapeutics Is Cheap, But FDA Decisions And OEM Pricing Still Rule - Finimize
Anika Therapeutics debuts Integrity and highlights portfolio at AAOS - Traders Union
Anika Therapeutics 2025 10-K: Revenue $112.8M, Diluted Loss per Share $(0.70) - TradingView
Anika Therapeutics Touts $3B TAM, Cingal & Hyalofast Growth Plans at Canaccord MSK Conference - Yahoo Finance
Anika Therapeutics, Inc. (ANIK) Presents at 2026 CG Musculoskeletal ConferenceSlideshow - Seeking Alpha
ANIK Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Anika Therapeutics (NASDAQ: ANIK) sharpens HA strategy with asset sales - Stock Titan
Does Anika Therapeutics, Inc. (ANIK) Have Momentum? - AAII
Anika Therapeutics Q4 Earnings Call Highlights - Defense World
Anika Therapeutics (NASDAQ:ANIK) Stock Price Expected to Rise, Barrington Research Analyst Says - Defense World
Anika Therapeutics (ANIK) Receives a Buy from B. Riley Securities - The Globe and Mail
ANIK | Anika Therapeutics Inc FinancialsIncome Statement - Quiver Quantitative
Anika Therapeutics (NASDAQ:ANIK) Announces Quarterly Earnings Results - MarketBeat
Barrington Research Forecasts Strong Price Appreciation for Anika Therapeutics (NASDAQ:ANIK) Stock - MarketBeat
ANIK: Barrington Research Raises Price Target to $17, Maintains 'Outperform' | ANIK Stock News - GuruFocus
Anika Therapeutics showcases Integrity benefits at ACFAS conference - Traders Union
Barrington Adjusts Price Target on Anika Therapeutics to $17 From $16, Maintains Outperform Rating - marketscreener.com
B. Riley Adjusts Price Target on Anika Therapeutics to $18 From $16, Maintains Buy Rating - marketscreener.com
Anika Therapeutics, Inc. (NASDAQ:ANIK) Q4 2025 Earnings Call Transcript - Insider Monkey
Anika Therapeutics, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:ANIK) 2026-02-27 - Seeking Alpha
Anika Therapeutics Inc (ANIK) Q4 2025 Earnings Call Highlights: - GuruFocus
Anika Therapeutics (ANIK) Q4 Earnings and Revenues Beat Estimates - Yahoo Finance
Earnings call transcript: Anika Therapeutics Q4 2025 results beat expectations - Investing.com
Anika Therapeutics (ANIK) Reports Consistent Q4 Revenue with Pro - GuruFocus
Earnings call transcript: Anika Therapeutics Q4 2025 results beat expectations By Investing.com - Investing.com Nigeria
Anika Therapeutics, Inc. Provides Earnings Guidance for the Full Year 2026 - marketscreener.com
ANIKA THERAPEUTICS ($ANIK) Releases Q4 2025 Earnings - Quiver Quantitative
Anika Announces Executive Transition Amid Stable Quarterly Results - TipRanks
Anika: Overview of Fourth Quarter Financial Results - Bitget
Anika: Q4 Earnings Snapshot - marketscreener.com
Anika Therapeutics extends transition agreement with Paul Colleran as EVP, General Counsel - TradingView
Anika (NASDAQ: ANIK) lifts margins as 2025 loss narrows sharply - Stock Titan
BRIEF-Anika Therapeutics Q4 Revenue USD 30.615 Million - TradingView
Anika Reports Fourth Quarter and Full Year 2025 Financial Results - GlobeNewswire
Anika Therapeutics cites 40 publications and 16 years of clinical data for Hyalofast cartilage repair - Traders Union
Trading the Move, Not the Narrative: (ANIK) Edition - Stock Traders Daily
Anika Therapeutics (NASDAQ:ANIK) Stock Passes Above 200 Day Moving AverageHere's What Happened - MarketBeat
Anika Therapeutics (ANIK) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
1.75%
1.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):